

Maternal Serotonergic Antidepressant Use in Pregnancy and Risk of Seizures in Children

Kelsey Kathleen Wiggs, BS, BA, Ayehsa C. Sujjan, PhD, Martin E. Rickert, PhD, et al.

Cite as: *Neurology*® 2022;98:e2329-e2336. doi:10.1212/WNL.0000000000200516

Correspondence

Ms. Wiggs
kkwiggs@iu.edu

Study Question

Do children born to women who use serotonergic antidepressants (i.e., selective serotonin reuptake inhibitors [SSRIs] and serotonin–norepinephrine reuptake inhibitors [SNRIs]) during pregnancy have higher risk of neonatal seizures and epilepsy?

What Is Known and What This Paper Adds

Several studies have documented an association between serotonergic antidepressant use in pregnancy and neonatal seizures in children, but few studies have examined whether these medications are associated with recurrent seizures (i.e., epilepsy). The current study aimed to expand the understanding of the potential effect of prenatal serotonergic antidepressant exposure on seizure outcomes using a nationwide sample of children by considering many confounders not incorporated in prior studies. This study provides Class II evidence that exposure to SSRIs/SNRIs in the first trimester of pregnancy is not associated with an increased incidence of neonatal seizures or epilepsy.

Methods

We used Swedish register-based data to examine associations between maternal reported use of SSRIs/SNRIs in pregnancy and neonatal seizures and epilepsy (using diagnosis codes) in a cohort of >1.2 million children. To examine the influence of confounding, we adjusted for a range of factors in a stepwise fashion: (1) maternal indication for SSRI/SNRI use (i.e., depression and anxiety), (2) parental epilepsy, and (3) parental background factors and pregnancy-specific characteristics. We used log-binomial regression to estimate the risk of neonatal seizures and Cox proportional hazard regression to estimate the risk of epilepsy.

Results and Study Limitations

Compared with unexposed children, children of women who reported SSRI/SNRI use in pregnancy had an elevated risk of neonatal seizures (risk ratio [RR] 1.41, 95% CI 1.03–1.94) and epilepsy (hazard ratio [HR] 1.21, 95% CI 1.03–1.43).

Table Associations Between Maternal Reported SSRI and SNRI Use During Pregnancy and Seizures in Children

	Unadjusted	Adjusted for maternal indications	Additionally adjusted for parental epilepsy	Additionally adjusted for all other covariates
Neonatal seizures (n = 1,551,906), RR (95% CI)	1.41 (1.03, 1.94)	1.30 (0.94, 1.80)	1.30 (0.94, 1.79)	1.10 (0.79, 1.53)
Epilepsy (n = 1,367,087), HR (95% CI)	1.21 (1.03, 1.43)	1.13 (0.95, 1.33)	1.11 (0.93, 1.31)	0.96 (0.81, 1.14)

Abbreviations: HR = hazard ratio; RR = risk ratio; SNRI = serotonin–norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor.

The estimates of association were attenuated by adjustment for maternal indications for SSRI/SNRI use (RR 1.30, 95% CI 0.94–1.80; HR 1.13, 95% CI 0.95–1.33), but not by additional adjustment for parental epilepsy history (RR 1.30, 95% CI 0.94–1.79; HR 1.11, 95% CI 0.93–1.31). Additional adjustment for parental and pregnancy-specific factors substantially attenuated the remaining associations (RR 1.10, 95% CI 0.79–1.53; HR 0.96, 95% CI 0.81–1.14). The findings suggest that associations are due to confounding factors rather than SSRI/SNRI use in pregnancy. Study limitations include possible misclassification of exposure and outcomes.

Study Funding and Competing Interests

This project was supported by the National Institute of Neurologic Disorders and Stroke, National Institute of Mental Health, National Institute on Drug Abuse of the NIH, the National Science Foundation, and the Swedish Research Council for Health, Working Life and Welfare. H Larsson has served as a speaker for Eli-Lilly and Shire and has received research grants from Shire, all outside the submitted work. Go to Neurology.org/N for full disclosures.

Neurology®

Maternal Serotonergic Antidepressant Use in Pregnancy and Risk of Seizures in Children

Kelsey Kathleen Wiggs, Ayehsa C. Sujan, Martin E. Rickert, et al.
Neurology 2022;98:e2329-e2336 Published Online before print May 11, 2022
DOI 10.1212/WNL.0000000000200516

This information is current as of May 11, 2022

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/98/23/e2329.full
References	This article cites 36 articles, 2 of which you can access for free at: http://n.neurology.org/content/98/23/e2329.full#ref-list-1
Citations	This article has been cited by 1 HighWire-hosted articles: http://n.neurology.org/content/98/23/e2329.full#otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All CBMRT/Null Hypothesis http://n.neurology.org/cgi/collection/all_cbmrt_null_hypothesis All Epilepsy/Seizures http://n.neurology.org/cgi/collection/all_epilepsy_seizures All Pediatric http://n.neurology.org/cgi/collection/all_pediatric Class II http://n.neurology.org/cgi/collection/class_ii Cohort studies http://n.neurology.org/cgi/collection/cohort_studies
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

